SK288131B6 - CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method - Google Patents

CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method Download PDF

Info

Publication number
SK288131B6
SK288131B6 SK1570-2002A SK15702002A SK288131B6 SK 288131 B6 SK288131 B6 SK 288131B6 SK 15702002 A SK15702002 A SK 15702002A SK 288131 B6 SK288131 B6 SK 288131B6
Authority
SK
Slovakia
Prior art keywords
ctla4
ctla4 mutant
molecule
mutant molecule
cell
Prior art date
Application number
SK1570-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK15702002A3 (sk
Inventor
Robert J. Peach
Joseph R. Naemura
Peter S. Linsley
Jurgen Bajorath
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK15702002A3 publication Critical patent/SK15702002A3/sk
Publication of SK288131B6 publication Critical patent/SK288131B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1570-2002A 2000-05-26 2001-05-23 CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method SK288131B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Publications (2)

Publication Number Publication Date
SK15702002A3 SK15702002A3 (sk) 2004-01-08
SK288131B6 true SK288131B6 (sk) 2013-10-02

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1570-2002A SK288131B6 (sk) 2000-05-26 2001-05-23 CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method

Country Status (41)

Country Link
EP (3) EP3029062A1 (zh)
JP (1) JP4328525B2 (zh)
KR (2) KR100889887B1 (zh)
CN (2) CN1309735C (zh)
AR (1) AR031699A1 (zh)
AT (1) ATE271066T1 (zh)
AU (2) AU6346601A (zh)
BE (1) BE2011C041I2 (zh)
BR (1) BRPI0111191B8 (zh)
CA (1) CA2409748C (zh)
CY (2) CY2011019I1 (zh)
CZ (1) CZ304451B6 (zh)
DE (2) DE60104282T2 (zh)
DK (1) DK1248802T3 (zh)
EC (1) ECSP024365A (zh)
EE (2) EE05458B1 (zh)
EG (1) EG24459A (zh)
ES (2) ES2571852T3 (zh)
FR (1) FR11C0053I2 (zh)
GE (1) GEP20053658B (zh)
HK (2) HK1048126B (zh)
HU (2) HU228137B1 (zh)
IL (1) IL152315A (zh)
LT (1) LT5133B (zh)
LU (1) LU91902I2 (zh)
LV (1) LV12994B (zh)
MX (1) MXPA02011534A (zh)
MY (1) MY136113A (zh)
NO (2) NO330797B1 (zh)
PE (1) PE20011338A1 (zh)
PL (1) PL206267B1 (zh)
PT (1) PT1248802E (zh)
RU (1) RU2283847C2 (zh)
SI (1) SI1248802T1 (zh)
SK (1) SK288131B6 (zh)
TR (1) TR200402703T4 (zh)
TW (2) TWI314933B (zh)
UA (1) UA87432C2 (zh)
UY (1) UY26723A1 (zh)
WO (1) WO2001092337A2 (zh)
ZA (1) ZA200208944B (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
KR100864120B1 (ko) * 2000-07-03 2008-10-16 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
EP1496931A4 (en) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
EP1575998A4 (en) 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
WO2005044188A2 (en) 2003-10-27 2005-05-19 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
KR101398713B1 (ko) 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008076487A2 (en) 2006-12-20 2008-06-26 Verenium Corporation Antibodies and methods for making and using them
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
ES2657220T3 (es) 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
CN102822198B (zh) * 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
EA201370187A1 (ru) 2011-02-23 2013-12-30 Амген Инк. Клеточная культуральная среда для уфс воздействия и относящиеся к ней способы
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
JP6228971B2 (ja) 2012-05-11 2017-11-08 メディミューン，エルエルシー Ｃｔｌａ−４バリアント
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
AU2013284460A1 (en) * 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
SG11201605640UA (en) 2014-01-13 2016-08-30 Amgen Inc Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
ES2709994T3 (es) 2014-06-04 2019-04-22 Amgen Inc Métodos de recolección en cultivos de células de mamífero
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
PE20221770A1 (es) 2019-12-06 2022-11-11 Regeneron Pharma Composiciones de proteina anti-vegf y metodos para producir la misma
MX2022016104A (es) 2020-06-18 2023-02-01 Regeneron Pharma Enfoque de peptidos pesados para medir con precision lisina de extremo c-terminal sin procesar.
AU2021315939A1 (en) 2020-07-28 2023-02-23 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
US20240010737A1 (en) 2022-03-02 2024-01-11 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
JP2003532370A (ja) * 1998-10-07 2003-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 新規なＴｈ２特異的分子およびその使用方法
KR100864120B1 (ko) * 2000-07-03 2008-10-16 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법

Also Published As

Publication number Publication date
HUP0302201A3 (en) 2010-01-28
CY1117625T1 (el) 2017-04-26
CZ304451B6 (cs) 2014-05-14
CN101255192A (zh) 2008-09-03
TW200906857A (en) 2009-02-16
CA2409748C (en) 2008-09-16
PL366231A1 (en) 2005-01-24
EG24459A (en) 2009-07-16
UA87432C2 (uk) 2009-07-27
ATE271066T1 (de) 2004-07-15
KR20030009502A (ko) 2003-01-29
HUP0302201A2 (hu) 2003-10-28
AU2001263466C1 (en) 2006-10-26
HUS1300012I1 (hu) 2016-08-29
ES2571852T3 (es) 2016-05-27
CY2011019I2 (el) 2016-12-14
TWI314933B (en) 2009-09-21
SK15702002A3 (sk) 2004-01-08
NO330797B1 (no) 2011-07-18
DE60104282D1 (de) 2004-08-19
EP1248802B9 (en) 2005-05-11
EP1248802B1 (en) 2004-07-14
CN1309735C (zh) 2007-04-11
RU2283847C2 (ru) 2006-09-20
ES2225549T3 (es) 2005-03-16
HK1048126B (zh) 2005-03-04
LV12994B (en) 2003-08-20
FR11C0053I2 (fr) 2013-01-11
DE60104282T2 (de) 2005-10-13
CZ20023892A3 (cs) 2003-09-17
NO2011027I1 (no) 2012-01-09
KR100895134B1 (ko) 2009-05-04
BR0111191A (pt) 2004-07-06
MY136113A (en) 2008-08-29
FR11C0053I1 (zh) 2012-01-13
LT2002114A (en) 2003-12-29
EE05458B1 (et) 2011-08-15
EP1536234B1 (en) 2016-03-16
HU228137B1 (en) 2012-12-28
MXPA02011534A (es) 2004-08-12
AU6346601A (en) 2001-12-11
EP1248802A2 (en) 2002-10-16
GEP20053658B (en) 2005-11-10
EE05557B1 (et) 2012-08-15
ECSP024365A (es) 2003-03-31
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
UY26723A1 (es) 2001-12-28
KR100889887B1 (ko) 2009-03-24
HK1048126A1 (en) 2003-03-21
NO20025656L (no) 2002-11-25
TR200402703T4 (tr) 2004-11-22
ZA200208944B (en) 2004-02-13
AU2001263466B2 (en) 2006-04-27
WO2001092337A3 (en) 2002-05-10
EP1536234A2 (en) 2005-06-01
IL152315A0 (en) 2003-05-29
LT5133B (lt) 2004-05-25
DK1248802T3 (da) 2004-11-15
WO2001092337A2 (en) 2001-12-06
TWI319405B (en) 2010-01-11
SI1248802T1 (en) 2005-02-28
JP2004511213A (ja) 2004-04-15
BRPI0111191B8 (pt) 2021-05-25
PL206267B1 (pl) 2010-07-30
AR031699A1 (es) 2003-10-01
PE20011338A1 (es) 2002-01-13
EP3029062A1 (en) 2016-06-08
IL152315A (en) 2010-04-15
CY2011019I1 (el) 2016-12-14
EE200200659A (et) 2004-06-15
NO2011027I2 (zh) 2011-12-15
CN1441810A (zh) 2003-09-10
BRPI0111191B1 (pt) 2019-12-31
HK1071931A1 (zh) 2005-08-05
JP4328525B2 (ja) 2009-09-09
DE122011100063I1 (de) 2012-06-14
EP1536234A3 (en) 2009-06-03
BE2011C041I2 (zh) 2020-08-20
CA2409748A1 (en) 2001-12-06
NO20025656D0 (no) 2002-11-25
EE201100050A (et) 2011-10-17
PT1248802E (pt) 2004-11-30

Similar Documents

Publication Publication Date Title
US20210115107A1 (en) Methods of treatment using ctla4 molecules
JP4328525B2 (ja) 可溶性ｃｔｌａ４突然変異体分子およびその用途
DK1935427T3 (en) APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES
AU2006203199B2 (en) Soluble CTLA4 mutant molecules and uses thereof
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF
NZ542231A (en) Soluble CTLA4 mutant fusion molecules and uses thereof
BG107210A (bg) Разтворими ctla4 мутантни молекули и тяхното използване

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - EU/1/11/694/002 20110617

Spc suppl protection certif: 5004-2014

Filing date: 20140210

SPCG Grant of an spc

Free format text: PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - EU/1/11/694/002 20110617

Spc suppl protection certif: 152 5004-2014

Filing date: 20140210

Extension date: 20260524

MK4A Patent expired

Expiry date: 20210523